Cabergoline treatment for surgery-naïve non-functioning pituitary macroadenomas
Authors' conclusion
Primary treatment with cabergoline is a reasonable approach for selected patients with NFPAs without visual threat.
Study context
- Population
- Surgery-naive patients with NFPA ≥ 10 mm, without chiasmal damage; mean age 63.3 ± 17.3 years, 56% males
- Participants
- 25 patients
- Outcome
- Tumor size change on MRI (growth: increase in maximal diameter ≥ 2 mm; shrinkage: reduction ≥ 2 mm)
- Follow-up
- Mean 4.6 ± 3.4 years
Main finding
As reported in the abstract
Tumor size change with cabergoline
Tumors decreased in size
5 (20%); mean decrease 5.0 ± 3.0 mm
Tumors remained stable
12
48%
Tumors increased in size
8 (32%); mean growth 5.0 ± 3.3 mm
Observational data: associations, not effects.
Further findings
Median tumor size change during first 2 years · first two years
- Median tumor size reduction
- 0.5 mm
Factors in tumor growth
- Patients with tumor increase had larger adenomas at diagnosis and longer follow-up
Surgery due to tumor enlargement
- Underwent surgery due to tumor enlargement
- 2 (8%)
Original publication
Cabergoline treatment for surgery-naïve non-functioning pituitary macroadenomas. Pituitary. Published 8 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →